Navigation Links
Avaxia Biologic's Barbara Fox Named one of Mass High Tech's Women to Watch in 2012

LEXINGTON, Mass., March 1, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that Dr. Barbara Fox, its founder and CEO, has been was named one of Mass High Tech's Women to Watch in 2012.  Mass High Tech's 9th annual Women to Watch awards recognize women in the fields of technology and life sciences, "who are go-getters, hardworking, inspirational and motivational to their peers."

Dr. David Poorvin, member of the Board of Directors of Avaxia, commented, "We are truly proud of this recognition of Dr. Fox's achievements.  She has been instrumental in building Avaxia Biologics from a creative idea into a developmental biotech company that will be testing its first drug candidate later this year. She is not only an innovative scientist, but also a motivational executive who leads by example.  We are confident that she will continue to have a significant impact on drug development and the biotech communities in Massachusetts for years to come."

Prior to founding Avaxia Biologics, Dr. Fox was the founder, President and Chief Scientific Officer of Recovery Pharmaceuticals, a company developing and marketing medications for the treatment of addiction. Prior to founding Recovery Pharmaceuticals in 1998, she was Vice President, Immunology at ImmuLogic Pharmaceutical Corp. She joined ImmuLogic in 1993, having served on the faculty of the University Maryland School of Medicine, Baltimore, as Associate Professor of Medicine with tenure in the Division of Rheumatology and Clinical Immunology, Dept. of Medicine. Dr. Fox received her BA in Chemistry from Bryn Mawr College and her Ph.D. in Chemistry from MIT. Dr. Fox trained as a post-doc in cellular immunology at the NIH.

Mass High Tech will honor Dr. Fox and 19 other awardees at an awards breakfast on Friday, May 11, 2012 at the Fairmont Copley Plaza.

About Avaxia Biologics, Inc.: Avaxia Biologics is a development-stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes and obesity.

SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
2. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
3. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
4. Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Companys Synthetic Biologics Strategic Focus
5. Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
6. Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development
7. BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility
8. Treatment of Patients With Malignant Mesothelioma Utilizing Photodynamic Therapy With Pinnacle Biologics Compound PHOTOFRIN® - Obtains FDA Orphan Drug Designation
9. ResearchMoz: Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)
10. US Biologics Market
11. BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
Post Your Comments:
(Date:11/29/2015)... 29, 2015   Royal Philips  (NYSE: PHG, AEX: ... at the 2015 Radiological Society of North America Annual ... Place in Chicago . Visitors to ... company,s broad portfolio of integrated Diagnostic Imaging, Clinical Informatics, ... clinical performance, improve workflow and create a superior patient ...
(Date:11/29/2015)... Nov. 29, 2015   National Decision Support Company ... client base, including notable statewide implementations. As a ... solution, ACR Select, more than 1 million times ... workflow. ACR Select provides real-time feedback on the ... and has been implemented at over 100 healthcare ...
(Date:11/27/2015)... PHILADELPHIA , Nov. 27, 2015  Lannett ... that it has completed the acquisition of Kremers ... pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A. ... --> Lannett has acquired KU from UCB ... to certain adjustments, including a customary working capital ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today ... Meeting. Their Ecosystem empowers dentists to make complex business decisions by providing the tools ... receive a free fee survey with 10 procedures customized by zip code. , ...
(Date:11/30/2015)... ... 30, 2015 , ... Scott Newman MD, FACS of New ... plastic surgeons in the New York City area to utilize the new, non-invasive ... heat-induced laser treatment for fat loss in the abdomen, flanks, and other areas ...
(Date:11/30/2015)... Atlanta, Georgia (PRWEB) , ... November 30, 2015 ... ... training for healthcare professionals worldwide today released the results of a survey of ... Middle East and Africa found a growing global demand for high quality online ...
(Date:11/30/2015)... Miami, FL (PRWEB) , ... November 30, 2015 ... ... manufacturer and engineer of patented products, announces the Unstoppable Swappables, a household invention ... Window Coverings Industry makes $2 billion a year and is growing at 2.6%," ...
(Date:11/29/2015)... Michigan (PRWEB) , ... November 29, 2015 , ... "I ... games. Things that as a Mother and Wife would love to do, I missed. ... that I just happened to call Dr. Zaidan first. They have changed my life ...
Breaking Medicine News(10 mins):